White matter tracts that overlap with the thalamus and the putamen are protected against multiple sclerosis pathology.


Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 13 07 2021
revised: 12 10 2021
accepted: 27 11 2021
pubmed: 19 12 2021
medline: 17 2 2022
entrez: 18 12 2021
Statut: ppublish

Résumé

The thalamus and the putamen are highly connected hubs implicated in multiple sclerosis (MS) pathology. It remains unclear if white matter (WM) tracts, which pass through them, have a different susceptibility to MS pathology, and if so, if their impact on disability predominates over that exerted by disease in other WM tracts. We hypothesized that WM tracts connected to and passing through these hubs (subsequently termed hub+ tracts) would be more susceptible to MS-related pathology than tracts that do not pass through them (hub- tracts) due to retrograde and anterograde distant degeneration. Thus, we compared the lesion load and neurite orientation dispersion and density imaging (NODDI) derived metrics between hub+ and hub- tracts and assessed the relationship between these MRI metrics and those of physical impairment. Eighteen patients (mean age of 45.5 years, 12 females) had 3 Tesla MRI consisting of T1-weighted and T2-weighted Fluid Attenuated Inversion Recovery (FLAIR), and NODDI from which the orientation dispersion index (ODI), neurite density index (NDI), and isotropic volume fraction (IVF) were derived. Forty-nine WM tracts, i.e., 12 hub+ and 37 hub- tracts, were segmented out. Exploratory analyses of the differences in lesion burden, whole tract and normal appearing WM (NAWM) NODDI metrics were carried out between the two types of tracts using a Mann-Whitney U test. Correlations with physical impairment, quantified using the expanded disability status scale (EDSS) and timed 25-foot walk (T25FW) test were assessed using Spearman correlation analyses. Hub- tracts had larger T1- (p<0.001) and T2-lesion (p<0.001) volumes; lower ODI (p<0.001), NDI (p<0.001) and higher IVF (p = 0.020) in comparison to hub+ tracts. Measures of tissue injury in hub+ tracts correlated with those of clinical disability, though less strongly than in hub- tracts. Contrary to our hypothesis, our exploratory pilot study results suggest that WM tracts that overlap with the thalamus and the putamen have a lower degree of lesional and non-lesional tissue injury, suggesting a protective role of the hubs against MS pathology or a higher degree of vulnerability of those not passing through hub stations. We also show a weaker association between disability impairment and hub+ pathology, compared to that in hub- tracts. Our findings point to a potential role of disease location in relation to hubs as guidance for treatment personalization in MS.

Sections du résumé

BACKGROUND BACKGROUND
The thalamus and the putamen are highly connected hubs implicated in multiple sclerosis (MS) pathology. It remains unclear if white matter (WM) tracts, which pass through them, have a different susceptibility to MS pathology, and if so, if their impact on disability predominates over that exerted by disease in other WM tracts. We hypothesized that WM tracts connected to and passing through these hubs (subsequently termed hub+ tracts) would be more susceptible to MS-related pathology than tracts that do not pass through them (hub- tracts) due to retrograde and anterograde distant degeneration. Thus, we compared the lesion load and neurite orientation dispersion and density imaging (NODDI) derived metrics between hub+ and hub- tracts and assessed the relationship between these MRI metrics and those of physical impairment.
METHODS METHODS
Eighteen patients (mean age of 45.5 years, 12 females) had 3 Tesla MRI consisting of T1-weighted and T2-weighted Fluid Attenuated Inversion Recovery (FLAIR), and NODDI from which the orientation dispersion index (ODI), neurite density index (NDI), and isotropic volume fraction (IVF) were derived. Forty-nine WM tracts, i.e., 12 hub+ and 37 hub- tracts, were segmented out. Exploratory analyses of the differences in lesion burden, whole tract and normal appearing WM (NAWM) NODDI metrics were carried out between the two types of tracts using a Mann-Whitney U test. Correlations with physical impairment, quantified using the expanded disability status scale (EDSS) and timed 25-foot walk (T25FW) test were assessed using Spearman correlation analyses.
RESULTS RESULTS
Hub- tracts had larger T1- (p<0.001) and T2-lesion (p<0.001) volumes; lower ODI (p<0.001), NDI (p<0.001) and higher IVF (p = 0.020) in comparison to hub+ tracts. Measures of tissue injury in hub+ tracts correlated with those of clinical disability, though less strongly than in hub- tracts.
CONCLUSIONS CONCLUSIONS
Contrary to our hypothesis, our exploratory pilot study results suggest that WM tracts that overlap with the thalamus and the putamen have a lower degree of lesional and non-lesional tissue injury, suggesting a protective role of the hubs against MS pathology or a higher degree of vulnerability of those not passing through hub stations. We also show a weaker association between disability impairment and hub+ pathology, compared to that in hub- tracts. Our findings point to a potential role of disease location in relation to hubs as guidance for treatment personalization in MS.

Identifiants

pubmed: 34922252
pii: S2211-0348(21)00696-9
doi: 10.1016/j.msard.2021.103430
pmc: PMC10703593
mid: NIHMS1817722
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103430

Subventions

Organisme : CSRD VA
ID : I01 CX002160
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA109106
Pays : United States
Organisme : NINDS NIH HHS
ID : R21 NS116434
Pays : United States

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Références

Neurol Neuroimmunol Neuroinflamm. 2015 Apr 09;2(3):e102
pubmed: 25884012
AJNR Am J Neuroradiol. 2020 May;41(5):751-757
pubmed: 32354707
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Neuroimage. 2012 Aug 15;62(2):782-90
pubmed: 21979382
Magn Reson Med. 2003 Nov;50(5):1077-88
pubmed: 14587019
Neuroimage. 2019 Oct 15;200:302-312
pubmed: 31260838
Neuroimage. 2004;23 Suppl 1:S208-19
pubmed: 15501092
J Neuroimaging. 2021 Sep;31(5):1003-1013
pubmed: 34033187
Neuroimage. 2009 Mar;45(1 Suppl):S173-86
pubmed: 19059349
Am J Psychiatry. 2005 Jul;162(7):1256-65
pubmed: 15994707
Annu Rev Neurosci. 1986;9:357-81
pubmed: 3085570
Hum Brain Mapp. 2010 Oct;31(10):1542-55
pubmed: 20108225
Neuron. 2011 Nov 3;72(3):443-54
pubmed: 22078504
Brain. 1999 May;122 ( Pt 5):871-82
pubmed: 10355672
Cereb Cortex. 2018 May 1;28(5):1685-1699
pubmed: 28334314
Neurology. 2013 Jan 15;80(3):234-41
pubmed: 23223533
Front Neurol. 2020 Jul 15;11:606
pubmed: 32760339
Ann Neurol. 2018 Feb;83(2):223-234
pubmed: 29328531
J Neurosurg. 2017 Mar;126(3):945-971
pubmed: 27257832
Brain. 2020 Jul 1;143(7):2089-2105
pubmed: 32572488
Brain. 1999 Jul;122 ( Pt 7):1261-70
pubmed: 10388792
Nat Neurosci. 2003 Jul;6(7):750-7
pubmed: 12808459
Lancet Digit Health. 2019 Sep;1(5):e222-e231
pubmed: 33323270
Int J Mol Sci. 2015 Sep 25;16(10):23195-209
pubmed: 26404239
Neural Plast. 2012;2012:823285
pubmed: 23326685
Neurology. 2021 Apr 6;96(14):e1865-e1875
pubmed: 33737372
Brain. 2018 Jun 1;141(6):1665-1677
pubmed: 29741648
PLoS One. 2014 Sep 18;9(9):e107263
pubmed: 25233361
Ann Clin Transl Neurol. 2019 Sep;6(9):1595-1605
pubmed: 31407532
Neuropsychol Rev. 2010 Jun;20(2):174-90
pubmed: 20411431
Neuroimage. 2006 Jul 1;31(3):968-80
pubmed: 16530430
Mult Scler Relat Disord. 2021 Apr;49:102738
pubmed: 33609957
Biol Psychiatry. 2007 Apr 15;61(8):935-45
pubmed: 17046727
Schizophr Res. 2006 Apr;83(2-3):155-71
pubmed: 16448806
Med Image Anal. 2008 Feb;12(1):26-41
pubmed: 17659998
Neurobiol Aging. 2020 Oct;94:15-23
pubmed: 32502831
Neuroimage Clin. 2016 Nov 25;13:106-115
pubmed: 27942453
Front Neurol. 2018 Oct 11;9:828
pubmed: 30364281
Neurol India. 2017 Jul-Aug;65(4):814-825
pubmed: 28681758
Ann Neurol. 2002 Nov;52(5):650-3
pubmed: 12402265
Neural Plast. 2012;2012:359728
pubmed: 22792492
J Neurol Neurosurg Psychiatry. 2008 Nov;79(11):1236-44
pubmed: 18469033

Auteurs

M A Clarke (MA)

Neuroimaging Unit, Neuro-immunology Division, Department of Neurology, Vanderbilt University Medical Center, Nashville TN, USA. Electronic address: margareta.clarke@vumc.org.

D Archer (D)

Vanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, USA.

K Yoon (K)

School of Medicine, Vanderbilt University, Nashville TN, USA.

I Oguz (I)

Department of Electrical Engineering and Computer Science, Vanderbilt University, Nashville TN, USA.

S A Smith (SA)

Department of Electrical Engineering and Computer Science, Vanderbilt University, Nashville TN, USA; Vanderbilt University Institute of Imaging Sciences, Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville TN, USA.

J Xu (J)

Vanderbilt University Institute of Imaging Sciences, Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville TN, USA.

G Cutter (G)

Department of Biostatistics, University of Alabama, Birmingham, AL, USA.

F Bagnato (F)

Neuroimaging Unit, Neuro-immunology Division, Department of Neurology, Vanderbilt University Medical Center, Nashville TN, USA; Department of Neurology, VA Medical Center, TN Valley Healthcare System (TVHS) Nashville TN, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH